An observational study in Conjunctival Diseases and Dry Eye Syndromes, sponsored by Fondation Ophtalmologique Adolphe de Rothschild. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-08.
Sponsored by Fondation Ophtalmologique Adolphe de Rothschild · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Dry Eye Syndromes with a site in France — 13 open to participants now, 14 under way, none of them phase 3. Dry Eye Syndromes · France.
Among the 47 studies in Dry Eye Syndromes with a site in France, this one is one of 4 that started in 2017, is one of 7 observational ones, reaches primary completion later than 6 of the 13 other live ones, and was the 12th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →13 of the 47 studies in Dry Eye Syndromes with a site in France are open now. Recruiting first, the newest first:
TRB Chemedica International SA · Sites in France, Belgium
Ages 18+
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18+
TRB Chemedica International SA · Sites in France, Austria
Ages 18+
AbbVie · Sites in France, United States, Netherlands
Ages 18–75
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 88 across 191 observational studies indexed under Dry Eye Syndromes.
Median enrollment 81 across the 40 interventional studies, 45 across the 7 observational. Of the 29 that completed or were terminated, 12 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 47 have an industry lead sponsor. The 10 most frequent:
Fondation Ophtalmologique Adolphe de Rothschild is the lead sponsor of 316 studies on the registry; 78 are open to participants now.
Fondation Ophtalmologique Adolphe de Rothschild has 4 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
5 of the studies in Dry Eye Syndromes with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03358979Fondation Ophtalmologique Adolphe de RothschildThree-dimensional Analysis of EMMPRIN on Conjunctival Epithelial Cells Surface in Severe Dry Eye Syndrome (ALTESSE) | 2026-12 |
| NCT05865379TRB Chemedica International SAEfficacy and Safety of BUFY01 Versus SVS20 in the Treatment of Dry Eye Disease | 2027-04 |
| NCT05865457TRB Chemedica International SAEfficacy and Safety of BUFY02 Versus TRB02 in the Treatment of Dry Eye Disease | 2027-04 |
| NCT04129021Centre Hospitalier National d'Ophtalmologie des Quinze-VingtsHigh Resolution, High-speed Multimodal Ophthalmic Imaging | 2027-07 |
| NCT07844408Essilor InternationalStudy of Eye Fatigue From Digital Screens and Its Impact on Visual Performance in People With Normal Vision and Myopia, With and Without Dry Eye Symptoms and Signs | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 47 studies in Dry Eye Syndromes with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Modifications of cell surface markers (including EMMPRIN) were observed in conjunctival epithelial cells during dry eye syndrome ; this study aims to describe the modifications of the repartition of these cell surface markers before and after initiation of a treatment.
Patients with severe eye dryness will be compared with persons without eye dryness.
Patients:
Inclusion criteria
Exclusion criteria - Known pregnancy or breastfeeding
Control subjects:
Inclusion criteria
- 18 years and over
Exclusion criteria
comparison of surface area of cell markers measured on conjunctival epithelial cells, in persons with and without severe eye dryness.
Comparison of the mean surface in patients before treatment for eye dryness versus in persons with no eye dryness. Immunofluorescence analysed in confocal microscopy on conjunctival impression cytology.
Time frame: baseline
Started Dec 2017 (actual). Primary completion is estimated for Dec 2026, 108 months after the start.
Of 53 non-industry observational studies under Dry Eye Syndromes, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 64. This study's planned 108 months is above that.
Counting every sponsor, half of 69 studies reached it within 12 months; a quarter within 5 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondation Ophtalmologique Adolphe de Rothschild →